Myriad Genetics Inc

Myriad Genetics announced the full commercial launch of FirstGene Multiple Prenatal Screen, a laboratory test that simultaneously performs four prenatal genetic screens from a single maternal blood draw as early as eight weeks of pregnancy. The test combines fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening into one report with results in about 10 days. It demonstrated more than 98% analytical sensitivity and more than 99% analytical specificity across its components. Myriad shares were trading down 0.70% at $5.88.

Myriad Genetics is the better-positioned stock in women's health diagnostics compared with Aspira Women's Health, according to a Zacks Investment Research analysis. Over the past three months, Aspira shares rose 2.5% while Myriad gained 20.4%, though Aspira rallied 81.8% over the past year versus Myriad's 38.5%. Aspira trades at a trailing 12-month enterprise value-to-sales multiple of 2.03, below its five-year median of 2.87, while Myriad's multiple sits at 0.70, below its five-year median of 2.07, both appearing attractively valued against the Zacks Medical sector average of 2.78. Myriad's diversified portfolio across oncology, women's health and mental health, broader commercial footprint and improving execution give it an edge over Aspira's narrower focus on gynecologic diagnostics and AI-powered test pipeline.

Myriad Genetics announced newly published data from the largest individual-patient-data meta-analysis of its Prolaris Biopsy Test, demonstrating that the test adds significant prognostic information beyond conventional clinical risk categories for patients with localized prostate cancer. The study, published in Clinical Genitourinary Cancer, pooled data from 14 studies involving 8,478 patients, with individual participant data available for 7,924 patients. Results showed that the Prolaris combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer-specific mortality across all NCCN risk groups and initial disease management strategies. The analysis provides further evidence that Prolaris offers independent, additive prognostic information beyond established clinical tools such as Gleason score, CAPRA score, and NCCN risk group. The Prolaris Biopsy Test analyzes gene expression from a prostate biopsy sample and incorporates clinical information to generate a CCR score intended to support initial prostate cancer management discussions, including active surveillance, definitive therapy, and multi-modal escalation.

Myriad Genetics shares surged 9.2% after the company expanded availability of its Precise MRD test for breast, colorectal, and renal cancers and announced positive clinical study results. The test, which monitors treatment response and cancer recurrence, is now accessible to over 6 million individuals in the U.S. living with these cancers. A study in breast cancer patients found that Precise MRD predicted a complete response to treatment with 100% specificity, and patients who tested positive for circulating tumor DNA after initial therapy were 47 times more likely to remain positive after surgery, highlighting the test's ability to identify those at higher risk for residual disease.

Myriad Genetics announced expanded availability of its Precise MRD test to patients with breast, colorectal and renal cancers, a move that broadens access to the ultrasensitive circulating tumor DNA assay for more than 6 million individuals living with these cancers in the U.S. The whole-genome sequencing-based test tracks up to 1,000 patient-specific variants and is designed for use across the cancer care continuum, from neoadjuvant therapy through post-surgical assessment and long-term surveillance. The company also published results from the prospective MONITOR-Breast study in Future Oncology, which showed that serial ctDNA monitoring during neoadjuvant therapy identified 44% more patients at risk for residual disease than testing at a single post-treatment timepoint alone. In the study of 154 patients with Stage I–III breast cancer, Precise MRD detected ctDNA in 93% of patients at baseline and predicted pathological complete response with 100% specificity, while patients who remained ctDNA positive at the end of neoadjuvant therapy were 47 times more likely to stay ctDNA positive after surgery.